Clinical trial
Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer
NCT00176605 · Rutgers, The State University of New Jersey, Other · Completed
Key facts
| NCT number | NCT00176605 |
|---|---|
| Title | Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer |
| Official title | A Phase II Trial of Metronomic Dosing of Etoposide and Cyclophosphamide in Patients With Stage D0 Prostate Cancer. |
| Lead sponsor | Rutgers, The State University of New Jersey, Other |
| Collaborators | National Cancer Institute (NCI) NIH Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Etoposide, Cyclophosphamide |
| Enrollment | 15 |
| Start date | May 1, 2005 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Sep 15, 2005 |
| Last update posted | May 20, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: